Image Image Image Image Image Image Image Image Image Image
Доступ
Идти наверх

Идти наверх

A differential treatment to ward off exudative AMD

02/11/2018 · новости
DMAE exudativa (JM El Periodico) RGB

It is vital not to halt the treatment in order to retain the maximum vision possible

Exudative AMD, a disease in which the Institut de la Màcula specialises, is an age-related macular degeneration that affects the area of the eye that allows us to see fine details clearly and causes loss of central vision.

vision DMAE x web-ENG 14Nov (1)

Sufferers have their autonomy reduced considerably and this affects their quality of life. It is therefore especially important to strive to retain the maximum vision possible. This may only be achieved by starting treatment quickly in the right way i.e. proactively and constantly.

riesgos DMAE x web-ENG 14Nov (1)

Exudative AMD is controlled through the application of anti-angiogenic drugs, through intraocular injections directly into the vitreous cavity. The drug acts by blocking the molecule that causes the development and progression of neovascular membranes. This treatment halts the disease in three of every four cases and improves it in one of every three.

The treatment the Institut provides for AMD possesses the maximum guarantees:

vision for more time, peace of mind and support

In order to achieve these results, it is vital to make an EARLY diagnosis when there are still no apparent symptoms or in the initial stages of the disease. This line of action is shared by all ophthalmologists although what often happens is that treatments are halted when the disease has stopped progressing without taking into account that this is a chronic condition. At the Institut de la Màcula, an institution that is a global benchmark in the field of AMD, we apply a differential treatment with the aim of warding off the disease by retaining the highest possible level of vision, this over an extended period of time. Our treatment has two cornerstones:

Proactive action

To prevent a reappearance of the disease it is essential for treatment to be proactive and take the lead, with the patient receiving the necessary number of intraocular injections. Unfortunately, we know that in many European countries, patients go under-treated, receiving on average six injections in two years. According to a variety of studies and scientific evidence alone, in the first year, the recommended number is a minimum of seven. At the Institut de la Màcula, we apply proactive agreed guidelines in order to optimise efficacy and safety outcomes, performing the injections that each patient needs.

Long-term treatment

The benefit obtained through the treatment needs to be maintained for as long as possible. Leading studies, such as those conducted by Australian research groups, show that sufficient treatment over a long period enables vision to be retained for many years. Regrettably, this is not common practice. At the Institut de la Màcula, our treatment is long term, with rigorous monitoring and extending whenever possible the application of intravitreal injections but without halting the treatment for years. This is the only way to retain vision beyond the short term.

Last modified: 2 July, 2020 - 11:57